Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Collaborates with Takeda on Hypertension Drug Discovery

NEW YORK, July 27 (GenomeWeb News) - Lexicon Genetics today announced it will collaborate with Takeda to develop new drugs for the treatment of high blood pressure.

 

Under the terms of the agreement, Takeda will have exclusive access to all drug targets that control blood pressure from Lexicon's Genome5000 program. Takeda will be responsible for screening, medicinal chemistry, preclinical and clinical development, and commercialization of drugs directed against Lexicon's targets, the company said.

 

Lexicon will receive an upfront payment of $12 million from Takeda for the initial, three-year term of the agreement. Takeda will have the option of extending the discovery portion of the alliance for an additional two years in exchange for further committed funding, Lexicon said. Lexicon will also earn royalties on worldwide sales of drugs commercialized by Takeda.

 

In the Genome5000 program, Lexicon is using gene knockout technology to discover the function of 5,000 of the most pharmaceutically important genes in the human genome, the company said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more